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Alzheimer’s disease is a devastating neurodegenerative disease with a dramatically increasing prevalence and no disease-modifying
treatment. Inflammatory lifestyle factors increase the risk of developing Alzheimer’s disease. Zinc deficiency is the most prevalent
malnutrition in the world and may be a risk factor for Alzheimer’s disease potentially through enhanced inflammation, although
evidence for this is limited. Here we provide epidemiological evidence suggesting that zinc supplementation was associated with
reduced risk and slower cognitive decline, in people with Alzheimer’s disease and mild cognitive impairment. Using the APP/PS1
mouse model of Alzheimer’s disease fed a control (35mg/kg zinc) or diet deficient in zinc (3mg/kg zinc), we determined that zinc
deficiency accelerated Alzheimer’s-like memory deficits without modifying amyloid b plaque burden in the brains of male mice.
The NLRP3-inflammasome complex is one of the most important regulators of inflammation, and we show here that zinc defi-
ciency in immune cells, including microglia, potentiated NLRP3 responses to inflammatory stimuli in vitro, including amyloid
oligomers, while zinc supplementation inhibited NLRP3 activation. APP/PS1 mice deficient in NLRP3 were protected against the
accelerated cognitive decline with zinc deficiency. Collectively, this research suggests that zinc status is linked to inflammatory reac-
tivity and may be modified in people to reduce the risk and slow the progression of Alzheimer’s disease.
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Significance Statement
Alzheimer’s disease is a common condition mostly affecting the elderly. Zinc deficiency is also a global problem, especially in
the elderly and also in people with Alzheimer’s disease. Zinc deficiency contributes to many clinical disorders, including
immune dysfunction. Inflammation is known to contribute to the risk and progression of Alzheimer’s disease; thus, we
hypothesized that zinc status would affect Alzheimer’s disease progression. Here we show that zinc supplementation reduced
the prevalence and symptomatic decline in people with Alzheimer’s disease. In an animal model of Alzheimer’s disease, zinc
deficiency worsened cognitive decline because of an enhancement in NLRP3-driven inflammation. Overall, our data suggest
that zinc status affects Alzheimer’s disease progression, and that zinc supplementation could slow the rate of cognitive
decline.
Introduction
The global prevalence of dementia (of which the most common
type is Alzheimer’s disease) is growing, with 152 million people pre-
dicted to be living with dementia by 2050 (from 50million in 2018),
and there are no effective treatments (Alzheimer’s Association,
2015). Approximately 92% of people living with dementia also suf-
fer from one or more long-term diseases (comorbidities) (Browne
et al., 2017). It has been established that disease-associated inflam-
mation increases the risk of developing dementia, and includes
inflammation associated with several comorbidities for Alzheimer’s
disease, such as infection, diabetes, atherosclerosis, and obesity
(Whitmer et al., 2005; Profenno et al., 2010). Zinc is an essential
trace element obtained from the diet that regulates the expression
and activation of many biological molecules. Maintenance of
adequate zinc levels through a balanced diet is therefore important
to health. Zinc deficiency affects up to 2 billion people worldwide
and has profound effects on immune system function (Prasad,
2012). Given its prevalence, therefore, it is likely that zinc deficiency
represents a significant comorbidity for Alzheimer’s disease that
could contribute to poorer quality of life and disease outcome.
Previous associations between zinc deficiency and Alzheimer’s dis-
ease include several studies reporting reduced plasma zinc levels in
people with Alzheimer’s disease (Ventriglia et al., 2015). Overall,
these data suggest that people with Alzheimer’s disease are at risk of
zinc deficiency, although the potential effect zinc deficiency is hav-
ing on the condition is currently debated.
Zinc is a critical micronutrient that plays an essential role in a
vast number of physiological processes; ;10% of proteins have
zinc binding domains; zinc also plays a role in membrane stabili-
zation and can act directly as a signaling molecule (Sensi et al.,
2009; Kambe et al., 2015). Because of its physiological impor-
tance, its cytosolic and extracellular concentrations are tightly
controlled by several mechanisms, including two main families
of transporters, the zinc transporters and the Zrt-Irt-related pro-
teins, as well as zinc storage proteins (e.g., metallothioneins) and
vesical storage of free zinc (Sensi et al., 2009; Kambe et al., 2015).
Typically, Zrt-Irt-related protein transporters act to increase cy-
tosolic concentrations of zinc, whereas zinc transporters act to
decrease cytosolic concentrations by movement of zinc out of
the cell or into cellular compartments, including vesicles, Golgi,
and endosomes (Sensi et al., 2009; Kambe et al., 2015). The ubiq-
uity and diversity of molecular functions that involve zinc have
made researching the interactions between zinc status and
Alzheimer’s disease difficult.
Several potential pathophysiological links of Alzheimer’s dis-
ease and zinc status have been investigated. The role zinc binding
has in amyloid fibril formation has been a substantial area of in-
terest. Several in vitro and in vivo studies report that excessive
zinc promotes the formation of amyloid oligomers and fibrils
through direct zinc-amyloid interactions. Amyloid oligomers
and fibrils are one of the pathologic hallmarks of Alzheimer’s
disease and considered a likely driver of the disease (Esler et al.,
1996; Brown et al., 1997; Lee et al., 2018). These findings have
driven preliminary Alzheimer’s clinical trials on compounds,
such as PBT2, which increase cellular uptake of zinc, thereby
reducing extracellular zinc levels. These trials have had largely
positive results (Faux et al., 2010).
Another focus of the Alzheimer’s disease zinc field is the role
of zinc proteases in beneficial and pathologic processes. Zinc is
an essential cofactor in a range of proteases, including proteases
that cleave the amyloid precursor protein into nonpathogenic
peptides, including the a-disintegrin and metalloproteinases
(Gough et al., 2011). Zinc is also a cofactor in proteases that
digest the pathologic forms of amyloid into nonoligomerizing
products, including the insulin-degrading enzyme (Gough et al.,
2011). Finally, the zinc protease matrix metallopeptidase 9 plays
a critical role in the healthy functioning of CNS, particularly the
activation of BDNF (Yang et al., 2014; Frazzini et al., 2018). BDNF
is an important neurotrophin that plays a role in neuronal plastic-
ity and synapse formation. Previously, the administration of zinc
chelators in mice has been shown to lower active BDNF levels
impairing cognitive performance (Yang et al., 2014; Frazzini et al.,
2018). While zinc and Alzheimer’s disease has been an active field
of research, little attention has been given to the known effects of
zinc status on immune function, particularly neuroinflammation,
an established driver of Alzheimer’s disease pathology.
We previously reported that zinc depletion of macrophages
activates an inflammatory complex called the NLRP3 (NACHT,
LRR, and PYD domains-containing protein 3) inflammasome
driving release of the pro-inflammatory cytokine interleukin-1b
(IL-1b ) from the cell (Summersgill et al., 2014). The NLRP3
inflammasome is formed in macrophages, and microglia in the
brain, in response to pathogenic or damage-associated stress and
drives an inflammatory response. The NLRP3 inflammasome
complex is composed of NLRP3, the adaptor protein ASC (apo-
ptosis-associated speck-like protein containing a caspase activa-
tion and recruitment domain), and the protease caspase-1, which
is responsible for cleaving the inactive precursor pro-IL-1b to
an active secreted IL-1b molecule (Brough et al., 2017; Heneka
et al., 2018). The NLRP3 inflammasome is suggested to contrib-
ute to the damaging inflammation that worsens Alzheimer’s dis-
ease (Heneka et al., 2013, 2018; Daniels et al., 2016; Dempsey et
al., 2017; White et al., 2017). NLRP3 is also suggested to contrib-
ute to age-related cognitive decline (Youm et al., 2013).
This study aimed to test the hypothesis that zinc status can
influence the development of Alzheimer’s disease. We report
here that zinc supplementation in people reduced the prevalence
and symptomatic decline of Alzheimer’s disease, and that zinc
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deficiency in an Alzheimer’s disease mouse model accelerated
cognitive decline through potentiation of NLRP3-dependent
inflammation, an effect that was reversible. These data suggest
that zinc deficiency is a treatable comorbidity, which, if man-
aged correctly, potentially through the use of zinc supplemen-




Data acquisition. Data used in the preparation of this article were
obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (http://adni.loni.usc.edu). The ADNI was launched in 2003 as a
public-private partnership, led by principal investigator Dr. Michael W.
Weiner. The primary goal of ADNI has been to test whether serial MRI,
PET, other biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression of mild cogni-
tive impairment (MCI) and early Alzheimer’s disease. The subjects were
recruited from over 50 sites across the United States and Canada. ADNI
has undergone three stages of recruitment each with differences in the
imaging and biomarker analyses, named ADNI-1, ADNI-GO, and
ADNI-2. Collectively, these protocols have recruited 1631 adults into the
study consisting of age-appropriate cognitively normal individuals, peo-
ple with early or late MCI, and people with early Alzheimer’s disease.
The follow-up duration of each group is specified in the protocols for
ADNI-1, ADNI-2, and ADNI-GO with 120months as the maximum.
Subjects were evaluated on entry into the study, then at the 6 and
12month time points, and yearly after this. For up-to-date information,
see www.adni-info.org.
Epidemiological analyses. Epidemiological analyses were performed
as described by Rivers-Auty et al. (2020). Briefly, datasets containing the
medical history (RECMHIST.csv), recurrent medicines (RECCMEDS.
csv), and patient summary data (ADNIMERGE.csv) were downloaded
on the third of May 2018. String search methods were applied to identify
patients using supplements. Baseline statistics were extracted, and logis-
tic regression was performed on Alzheimer’s disease prevalence to evalu-
ate the association between supplement use and Alzheimer’s disease risk.
Negative binomial generalized linear mixed modeling (GLMM) was
applied to the number of failures that occurred during the Mini-Mental
State Examination (MMSE). Variables were included in the models both
as a fixed effect and as an interaction effect with time. Variables included
in the analyses were diagnosis (control, MCI, or Alzheimer’s disease),
age, gender, APOE4 genotype, education level, headaches, arthritis, dia-
betes, smoking, cardiovascular risk factors, and supplement use. The sig-
nificance of variable inclusion for the logistic regression and GLMMwas
evaluated using the log likelihood ratio test, estimated by a x 2 distribu-
tion. To construct the negative binomial GLMM models, the package
glmmadmb was used (Fournier et al., 2012; Skaug et al., 2013); logistic
regression used the LME4 package (Bates et al., 2015), both on R version
3.5.1 (R Core Team, 2018) with RStudio version 1.1.453 (RStudio Team,
2016). Details of the full analysis can be found in the Extended Data,
which contains the annotated R code and output of the epidemiological
analysis of the Alzheimer’s disease neuroimaging cohort study.
Animal experiments
Animals were housed in individually ventilated cages maintained at
21 6 2°C with 40%-50% humidity on a standard 12 h light/dark cycle
and free access to water and food. Before experiment, all animals were
on standard rodent chow (BK001 E, Special Diets Services). Genotyping
was performed by Transnetyx, and these results were not revealed until
the end of all behavioral, histologic, or physiological investigations had
been completed. Thus, all experiments were performed blinded to geno-
type. All behavioral videos, physiological analyses, and histologic quanti-
fications were recoded to blind the experimenter to both genotype and
diet. Diet was randomly allocated by cage using the TrueRandom soft-
ware. All behavioral experiments were performed with 40 dB white noise
played in surround sound to avoid auditory cues. All animal
experiments were conducted in accordance with the United Kingdom
Animals (Scientific Procedures) Act 1986 and approved by the Home
Office and the local Animal Ethical Review Group, University of
Manchester.
The effect of zinc deficiency in APP/PS1 mice. APPswe PSEN1DE9
(APP/PS1) transgenic mice on a C57BL/6J background were obtained
from The Jackson Laboratory (#005864). Hemizygous male APP/PS1
mice were bred with C57BL/6J female mice to generate litters of hemizy-
gous APP/PS1 and C57BL/6J (WT) littermate controls, of which the
males were used in the experiments. At 3 months of age, the animals
underwent baseline behavioral testing and were then randomly allocated
to a zinc normal (ZN) diet (35mg/kg, Table 1) or zinc deficient (ZD)
diet (3mg/kg, Table 1). Two-thirds of the mice were initially placed on a
ZD diet and one-third were placed on a ZN diet. After 3 months on diet,
another set of behavioral tests were performed. Then half the cages on a
ZD diet were randomly allocated to be placed on the ZN diet. All mice
remained on diet for another 3 months, which was followed by another
set of behavioral experiments after which mice were killed by exsangui-
nation and cardiac perfusion with saline under isoflurane (2%-5%) anes-
thesia. A power analysis was performed using the standardized effect
size based on an ordinary least squares repeated-measures method. A
moderate partial h2 of 0.15 was selected with an a of 0.05 and a b of
0.2. From this, it was found that an n of 10 was required. To account for
attrition and fluctuations in genotype prevalence, a target of n= 13 was
selected. Final numbers (n) in each group were as follows: WT ZN=13;
WT ZD=15; WT ZD/ZN=12; APP/PS1 ZN=13; APP/PS1 ZD=11;
APP/PS1 ZD/ZN=11.
The effect of zinc deficiency in aged C57BL/6J mice. At 3 months
(Young) or 20months (Aged) of age, C57BL/6J mice had their baseline
memory performance probed using the Y-maze task, before being ran-
domly allocated to a ZD or ZN diet for 3 months (n=15 per group). All
mice were then evaluated in the Y-maze and culled by exsanguination
and cardiac perfusion with saline under isoflurane (2%-5%) anesthesia.
Using the same power analysis as above, an n of 15 was selected to
account for the greater potential of attrition.
The effect of zinc deficiency in APP/PS1 mice deficient in NLRP3.
Mice lacking nlrp3 (nlrp3/) on a C57BL/6J background mice were
provided by Vishva Dixit (Genentech) (Mariathasan et al., 2006). These
mice were backcrossed with the APP/PS1 line for 6 generations and then
bred into two colonies containing APP/PS1/nlrp3/ hemizygous male
and WT/nlrp3/ (WT are C57BL/6J) female breeders, and APP/PS1/
nlrp31/1 hemizygous male and WT/nlrp31/1 female breeders. These
were used to generate the experimental male mice used in this study. At
3 months of age, cages of mice were randomly allocated onto either a
ZD or ZN diet. After 6 months on diet, memory of all mice was assessed
with the Y-maze task. The animals were then killed by exsanguination
Table 1. Diet compositiona
Diet component g/kg






Mineral mix (zinc absent) 35
Calcium phosphate, dibasic 3
Chromium potassium sulfate, dodecahydrate 0.01
Vitamin mix AIN 93 10
Biotin 0.004
p-Aminobenzoic acid 0.11
Vitamin C, ascorbic acid, coated (97.5%) 1.017
Choline bitartrate 3
Inositol 0.11
Zinc chloride (3 mg/kg) (ZD) 0.0052
Zinc chloride (35 mg/kg) (ZN) 0.0719
aThe composition of the ZN (35 mg/kg) and ZD (3 mg/kg) diets were identical apart from the amount of
zinc.
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and cardiac perfusion with saline under isoflurane (2%-5%) anesthesia.
The primary outcome of Y-maze performance after 6months on diet
was selected. Using the data obtained in the zinc deficiency experiment
above, the mean difference of 13.4 and a pooled SD of 7.6 was used with
an a of 0.05 and a b of 0.2. This analysis found that an n of 9 mice per
group was required for the Sidak corrected post hoc analysis with 6 com-
parisons. To account for attrition and fluctuations in genotype preva-
lence, a target n= 10 was selected. Final numbers (n) in each group were
as follows: WT/nlrp31/1 ZN=12; WT/nlrp31/1 ZD=14; WT/nlrp3/
ZN=8; WT/nlrp3/ ZD=9; APP/PS1/nlrp31/1 ZN=8; APP/PS1/
nlrp31/1 ZD=11; APP/PS1/nlrp3/ ZN=13; APP/PS1/nlrp3/
ZD=9.
Y-maze task. The Y-maze consisted of three connected small rooms
each with a unique visual cue on the back wall. Mice were placed in the
maze using the tube transfer method and allowed to explore for 8min.
The exploration was recorded, and the videos were then recoded and
scored by an observer blinded to the experimental groups. A successful
set of alternations was defined as entering all three rooms in succession
with no repeated room entries. Performance was expressed as the per-
centage of total alternation sets which were successful. The mazes were
thoroughly cleaned with 70% ethanol and then dried with paper towels
between animals to avoid olfactory cues. Trials in which the mouse com-
pleted,9 entries were excluded.
Novel smell task. The novel smell task was performed in a cylindrical
arena. The mice were first habituated to the arena without olfactory cues
by being placed in the arena using the tube transfer method for 8min.
The following day, the mice were placed in the arena for 8min with two
olfactory cue dispensers with identical smells. They were then placed in
holding cages for 8min, while the arenas were cleaned with ethanol and
dried, and the olfactory dispensers were changed to consist of a novel
and familiar smell. The mice were then placed back in the area and
recorded for 4min. The exploration was recorded, and the videos were
then recoded and timed using the Novel Object Timer program (https://
jackauty.com/program/) by an observer blinded to the experimental
groups as described by Daniels et al. (2016). Trials in which the mouse
completed,4 s of exploration were excluded.
Tissue processing. Mice were terminally anesthetized with 2%-5%
isoflurane (30% O2, 70% N2O). Plasma was collected via cardiac punc-
ture using citrate-treated needles, followed by trans-cardiac perfusion
with 0.9% saline. Femurs were taken for inductively coupled plasma
mass spectrometry of the bone, and one epididymal fat pad was removed
and weighed. Brains were dissected into hemispheres. The left hippo-
campus was extracted and snap frozen for RNA sequencing. RNA was
extracted using a QIAGEN mini-kit as per instructions and tested for
purity and concentration using the nano-drop method and analyzed for
purity and digestion with a TAPE station. All samples had RNA integrity
numbers of .8.5. RNAseq was performed as described by Hoyle et al.
(2018) on an Illumina HiSeq4000 instrument. The right hemisphere was
immerse-fixed in 4% PFA for 24 h and cryoprotected in 30% sucrose
before being snap frozen and sectioned (15mm) coronally every 90mm
from the rostral end of the cortex (for experiment in Figs. 2, 3A-C),
or immerse-fixed in 4% PFA for 24 h, then dehydrated, paraffin-embed-
ded, and sectioned (5mm) every 100mm from the central sulcus (for
experiment in Fig. 5) and mounted onto Superfrost Plus slides (VWR).
Six sections evenly spaced throughout the cortex were selected for
immunohistochemistry. Paraffin sections were deparaffinized with xy-
lene emersion and rehydrated in descending concentrations of ethanol.
For all sections, antigen retrieval consisted of 30min immersion in 0.2
mM citrate buffer, pH 6, at 96°C followed by 10min in 90% formic acid.
Sections were washed (3 5min) with 0.1% Tween in PBS (PBST),
blocked for 1 h in a 1% BSA (A9647 Sigma Millipore), 0.2 M PB solution,
and then incubated overnight in 1:200 biotinylated 6e10 antibody (for
amyloid b [Ab ] plaques; #SIG-39 340-200, Covance) or 1:1000 Iba1
(for microglia; Wako) in a 1% BSA, 0.2 M PB solution at 4°C. Sections
were then washed (3 5min, PBST), incubated with biotinylated anti-
mouse secondary (Iba1), or/followed by 1:20 Strep-Avidin (P188503,
RnD)/1% BSA, 0.2 M PB solution for 2 h at room temperature, washed
and then visualized with a DAB nickel solution (D0426-50SET, Sigma
Millipore). Sections were dehydrated in serial ethanol solutions of
increasing concentration and then 100% xylene, and then mounted with
DPX (DI5319/05, Thermo Fisher Scientific). The slides were scanned,
and the images recoded. Ab plaque burden, approximated as percentage
stained area, was calculated using threshold-particle analyses performed
on ImageJ. The microglial activation stage was performed as in Daniels
et al. (2016).
Laser microdissection. Eight- to 9-month-old APP/PS1 and C57B/6J
littermate mice were terminally anesthetized with 2-5% isoflurane
(30% O2, 70% N2O) followed by trans-cardiac perfusion with 0.9% sa-
line. Brains were harvested, snap frozen using dry ice, and stored at
80°C until analyzed. Coronal 30mm brain sections were taken from
the hippocampal region using Leica Microsystems CM3050 S cryostat
and mounted onto RNase-free membrane-coated microscopy slides
(Molecular Machines & Industries). The slides were stained by
immersion in a filtered Congo red solution (0.2% Congo red solution
in 20% NaCl, 80% ethanol, pH 9.0) for 20min at room temperature.
Using the laser microdissection (LMD) MMI (Molecular Machines &
Industries) SmartCut software, UV laser excised discs of a fixed
100mm diameter with Congo red-stained amyloid plaques in the
center were cut (see Fig. 3H). Plaque-free tissue from both the same
animals and WT littermate controls were also cut and collected sep-
arately. Once cut, microdissected regions were acquired using
mechanically operated adhesive MMI Isolation Caps (Molecular
Machines & Industries), which were subsequently filled with the
lysis buffer component of RNeasy Micro Kit (QIAGEN). On com-
pletion of LMD, sample-containing microcentrifuge tubes immedi-
ately underwent lysis via freeze-thaw cycling and brief (,5 s)
sonication. Purified RNA was acquired as per RNeasy Micro Kit
(QIAGEN) instructions with on-column DNase digestion and wash-
ing according to the manufacturer’s guidelines. Images were col-
lected on an Olympus IX83 inverted microscope modified for LMD
capture.
Inductively coupled plasma mass spectrometry. Inductively coupled
plasma mass spectrometry (Agilent Technologies, 7900) was used to
assess zinc levels in the plasma and bone. The diets, bedding, drinking
water, and cage materials were also measured for zinc content before the
start of the experiments. As a result of these analyses, the bedding was
changed to the low zinc nesting material WoodWool (TAPVEI). Plasma
samples were diluted in 1:10 with 0.1 M hydrochloric acid, centrifuged
(2500  g), and then analyzed with appropriate standards generated.
Whole femurs were taken from the mice and wet-ashed by HNO3 (0.5
ml, concentrated) immersion at room temperature for 24 h, then dried
at 60°C. After cooling, 0.2 ml of H2O2 was added and the samples were
incubated for 1 h in a drying oven at 60°C. The solutions were diluted to
10 ml using deionized water and analyzed.
qRT-PCR. Isolated RNA was reverse-transcribed using Tetro cDNA
Synthesis Kit (Bioline), with samples being incubated at 25°C for 10min,
45°C for 30min, and 85°C for 5min. cDNA was subjected to qPCR
using the 7900HT Fast Real-Time PCR detection system (Applied
Biosystems) Power SYBR Green Master Mix (Applied Biosystems). A
standard amplification program (1 2min cycle at 50°C, 1 10min
cycle at 95°C, 50 15 s cycle at 95°C, and 1 1min cycle at 60°C) was
used for all amplifications. Primers used for the amplification were as
follows: trem2 (forward, TGGGGACCTCTCCACCAGTT; reverse,
GTGGTGTTGAGGGCTTGG), nlrp3 (forward, GCCCAAGGAGGA
AGAAGAAG; reverse, TCCGGTTGGTGCTTAGACTT), and il-1b
(forward, AACCTGCTGGTGTGTGACGTTC; reverse, CAGCACGA
GGCTTTTTTGTTGT). Standard curves of serial control cDNA dilu-
tions were used to determine the fold differences in target cDNA expres-
sion. Hmbs was used as the housekeeping gene (forward, GAAATCAT
TGCTATGTCCACCA; reverse, GCGTTTTCTAGCTCCTTGGTAA).
Cell isolation and culture
Bone-marrow derived macrophages (BMDMs). All primary cells
were harvested from 8- to 16-week-old, mixed sex, C57/BL6J mice
(Charles River), which were killed with rising CO2 concentration.
Murine BMDMs were generated as reported previously by Daniels et al.
(2016). Briefly, BMDMs were collected by flushing bone marrow from
femurs and cultured in DMEM (Invitrogen) supplemented with 10%
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FBS (Biowest), 1% PenStrep, 2 mM, 1% L-glutamine (Sigma Millipore),
and 20% macrophage colony-stimulating factor-conditioned medium
from L929 cells. Cells were grown for 7 d and then scraped, counted, and
seeded for 24 h in 24- to 96-well plates at 1 106 cells/ml in complete
DMEM. After media change, cells were primed with bacterial endotoxin
(lipopolysaccharide [LPS], 1mg/ml) from Escherichia coli O26:B6, for 4
h. The media was changed to serum-free DMEM before treatment with
pathway inhibitors (MCC950 10 mM or ZnCl2) or vehicle (DMSO) for
15min followed by stimuli treatment for 4 h with TPEN (N,N,N9,N9-tet-
rakis(2-pyridinylmethyl)1,2-ethanediamine), or silica (,15mm, MIN-
U-SIL 15; 300mg/ml), or 24 h for amyloid 1-42 (Sigma Millipore,
oligomerized at 37°C for 24 h in PBS before treatment; NB for amyloid,
cells without LPS-priming were used). Supernatants were taken for
ELISA IL-1b and Western blot. An in-well lysis was performed with 1%
Triton for Western blot analyses of cytosolic and secreted proteins.
Mixed glia.Murine mixed glia cells were prepared from the brains of
2- to 4-day-old C57BL/6J mixed sex mice. Briefly, the cerebral hemi-
spheres were dissected, and the meninges were then removed. The
remaining tissue was homogenized in DMEM containing 10% FBS and
PenStrep via repeated trituration. The resulting homogenate was centri-
fuged at 500  g for 10min, and the pellet was resuspended in fresh cul-
ture medium, seeded directly into 24-well plates, and incubated at 37°C,
90% humidity, and 5% CO2. After 5 d, the cells were washed, and fresh
medium was placed on the cells. The medium was then replaced every
2 d. Cells were used after 2 weeks. Cells were primed with LPS (1mg/ml,
3 h) in DMEM containing 10% FBS and PenStrep. For zinc chelation
experiments, cells were washed once with serum-free DMEM before
treatment with serum-free DMEM containing vehicle (DMSO) or TPEN
(20 mM, 4 h) with or without silica (300mg/ml) or MCC950 (10 mM). For
the amyloid experiment, LPS-primed cells were made zinc-deficient
(TPEN, 10mM) and incubated in amyloid oligomers (10mg/ml, 4 h). The
supernatant was centrifuged at 12,000  g for 10min before analysis for
IL-1b content by ELISA.
ELISA and Western blot. IL-1b release was quantified by ELISA
(DuoSet, R&D Systems) according to the manufacturer’s instructions.
IL-1b , gasdermin D, and caspase-1 cleavage was determined by
Western blot. All supernatants or in-well lysates were separated by 12-
well, 1.5 mm Tris-glycine SDS/PAGE and then transferred onto nitrocel-
lulose or PVDF membranes at 25 V using a semidry Trans-Blot Turbo
system (Bio-Rad). Membrane blocking was performed using in 2% BSA
in 1% (v/v) Tween 20/PBS (PBST). Membranes were then incubated
with primary antibodies at 4°C overnight (IL-1b AF-401, R&D Systems;
gasdermin D ab209845, Abcam; and caspase-1 EPR16883, Abcam),
washed and then labeled with HRP-conjugated secondary antibodies
(2 h at room temperature). Target proteins were then visualized with GE
HealthcareECL detection reagent (GE Healthcare) using the G:Box
Chemi XX6 (Syngene) system.
ASC oligomerization assay. Cells were lysed in-well with 1% Triton
X-100 and protease inhibitor cocktail. Cell lysates were centrifuged at
6800  g for 20min at 4°C to separate the Triton X-100-soluble and -in-
soluble fraction. The Triton X-100-insoluble fraction was chemically
crosslinked with 2 mM disuccinimidyl suberate (Thermo Fisher Scientific)
for 30min at room temperature. Crosslinked pellets were precipitated by
centrifugation at 6800 g for 20min and resuspended in Laemmli buffer.
Oligomerized ASCs were then detected byWestern blot.
ASC speck formation. Adult microglia were extracted from 8- to 16-
week-old, mixed sex, C57/BL6J mice expressing ASC-citrine on a CAG
promoter using MACS MicroBeads on digested brains as per themanu-
facturer’s instructions. Microglia were seeded for 2 h into 96-well plates
at 0.5 105/ml. They were primed with LPS (1mg/ml, 2 h). All cells were
treated with the pan-caspase inhibitor Z-VAD-FMK (50 mM) before
simulation to prevent caspase-dependent cell death. Without media
change, NBC19 (10 mM), MCC950 (10 mM), or vehicle (DMSO) was
spiked into the appropriate wells, followed by TPEN administration
(final concentration 10 mM). At 15 min intervals, images were cap-
tured using a 20/0.61 S Plan Fluor objective for a total of 12 h.
Speck formation was quantified using an IncuCyte ZOOM System
(Essen Bioscience). All experiments performed in serum-free
OptiMEM.
Experimental statistics
All data are presented as mean values6 SEM unless stated. For
repeated-measures analyses, linear mixed modeling was used to evaluate
the significance of the effect of independent factors (genotype, diet, and
time) on the dependent variable. All factors and interactions were mod-
eled as fixed effects and mouse identifier as a random variable. A within-
subject design with random intercepts was used for all models. The sig-
nificance of inclusion of an independent variable or interaction terms
was evaluated using log-likelihood ratio (Bates et al., 2015). Holm-Sidak
post hoc was then performed for planned pairwise comparisons using
approximated least square means (Lenth, 2016). For the remaining data,
statistical analyses were unpaired Welch corrected Student’s t test, or
one-way, two-way, or three-way ANOVA test depending on the number
of experimental groups and independent variables in the analyses.
Holm-Sidak post hoc was then performed for planned pairwise compari-
sons. Homoscedasticity and normality were evaluated graphically using
predicted versus (Pearson) residuals and Q-Q plots, respectively, and
transformations and/or corrections were applied where necessary. All
analyses were performed using R (version 3.3.3) (R Core Team, 2018;
RStudio Team, 2016).
Results
Zinc supplementation use is associated with reduced
prevalence of Alzheimer’s disease and slower cognitive
decline during disease development
The ADNI dataset was used to investigate the effects of
mineral supplementation on both the prevalence of cognitive
dysfunction, including early and late MCI, and Alzheimer’s
disease, as well as the progression of cognitive decline over
time. Investigating the six most common mineral supplements
(calcium, iron, magnesium, multivitamin, selenium, zinc),
and using logistic regression adjusting for common confound-
ing variables, we found that calcium, iron, magnesium, and
zinc supplement use was associated with significantly reduced
Alzheimer’s disease prevalence compared with those not tak-
ing any supplements (Fig. 1A,B). To further investigate the
potential effects of mineral supplementation, innovative sta-
tistical methods for analyzing cognitive decline, as measured
by the MMSE, were used. From this, it was found that zinc
supplementation was associated with significantly less cogni-
tive decline (Fig. 1C,E). Other supplements, including the
divalent cations calcium and magnesium, were not associated
with significant changes in cognitive decline (Fig. 1D).
Subclinical zinc deficiency accelerates memory deficits in an
animal model of Alzheimer’s disease without effecting
plasma zinc or weight gain
We then sought to establish that the association between zinc
supplementation and improved Alzheimer’s disease outcome
was causal by using the APP/PS1 mouse model of Alzheimer’s
disease. WT control or APP/PS1 mice were fed a diet containing
the recommended zinc intake levels for mice (35mg/kg, ZN) or
a diet that would induce a mild subclinical zinc deficiency (3mg/
kg, ZD) (Fig. 2A). Animals were put on diet from 3 months of
age and maintained for 6 months with memory tests (Y-maze
and novel smell test) performed at 3 month intervals (Fig. 2A).
To determine whether any effects of zinc deficiency were reversi-
ble, one group of mice was maintained on a ZD diet for 3 months
and then placed on a normal zinc diet for 3 months (Fig. 2A).
APP/PS1 mice do not show altered cognitive behavior in short-
term memory tasks, such as the Y-maze, T-maze, or novel object
recognition before 9 months of age (Webster et al., 2014). At the
end of the experimental period, animals were killed, zinc levels
measured in the plasma and bone, and a number of histologic
and physiological measures were taken, including RNAseq on
hippocampal tissue, and analyses on Ab plaque burden and
Rivers-Auty et al. · Zinc Status, Inflammation, and Alzheimer’s Disease J. Neurosci., March 31, 2021 • 41(13):3025–3038 • 3029
No supplement Calcium Iron Magnesium Multi-vitamin Selenium Zinc Statistics
Diagnosis
   CN 131 (20%) 185 (31%) 35 (32%) 60 (37%) 161 (31%) 17 (40%) 20 (31%) X2(18)=92.5
   EMCI 129 (20%) 116 (20%) 29 (26%) 32 (20%) 70 (13%) 3 (7%) 15 (23%) p<0.0001
   LMCI 219 (33%) 199 (33%) 37 (33%) 54 (33%) 199 (31%) 18 (42%) 26 (40%)






   Male 232 (35%) 385 (65%) 56 (50%) 91 (56%) 200 (38%) 14 (33%) 25 (38%) X2(6)=143.0




   -/- 315 (48%) 321 (54%) 68 (61%) 86 (53%) 292 (56%) 23 (55%) 37 (57%) X2(12)=15.3
   +/- 261 (40%) 209 (35%) 32 (29%) 62 (38%) 185 (35%) 16 (36%) 25 (38%) p=0.223
   +/+ 79 (12%) 59 (10%) 11 (10%) 14 (9%) 47 (9%) 4 (9%) 3 (5%)
Education
   Primary 223 (34%) 200 (34%) 37 (33%) 57 (35%) 193 (37%) 26 (60%) 22 (34%) X2(18)=29.3
   Secondary 197 (37%) 155 (26%) 26 (23%) 48 (30%) 151 (29%) 10 (23%) 24 (37%) p=0.045
   Tertiary 115 (15%) 136 (23%) 30 (27%) 30 (19%) 102 (20%) 4 (9%) 10 (15%)











Total 655 509 111 162 524 43 65
11 (24%) 11 (16%)
Cardiovascular risk
factors
413 (63%) 346 (59%) 70 (63%) 91 (56%) 322 (61%) 25 (58%) 40 (61%)
Smoker 176 (27%) 140 (24%) 30 (27%) 44 (27%) 129 (24%)
19 (44%) 31 (48%)
Diabetes 42 (4%) 37 (4%) 14 (8%) 9 (4%) 47 (6%) 2 (3%) 7 (7%)
Arthritis 213 (33%) 261 (44%) 57 (51%) 70 (43%) 226 (43%)
74.5 (6.2)ns 73.4 (7.1)ns
Headache 42 (6%) 65 (11%) 10 (9%) 14 (8%) 48 (9%) 5 (11%) 4 (6%)
Age (mean, SD) 73.7 (7.5) 73.8 (7.0)** 74.3 (7.1)ns 72.9 (6.7)* 74.4 (7.1)*
14.7 (7.0)ns 14.2 (6.9)ns
MMSE (mean, SD) 26.4 (2.8) 27.3 (2.6)*** 27.2 (2.6)ns 28.0 (2.4)* 27.7 (2.2)ns 27.6 (2.4)ns 27.4 (2.5)ns
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   CN - - - - - -
   EMCI 0.708 0.066 p<0.00001 X2(3)=1147 -0.00332 0.0010 p=0.00145 X2(3)79.85
   LMCI 1.242 0.056 p<0.00001 p<0.00001 0.00286 0.0007 p=0.00008 p<0.00001
   AD 2.11 0.062 p<0.00001 0.00880 0.0014 p<0.00001
Age (mean, SD) 0.018 0.003 p<0.00001 X
2(1)=48.2
p<0.00001
- - - -
Gender
   Male - - - X2(1)=2.2 - - - X2(2)=8.4
   Female 0.096 0.040 p=0.01806 p=0.138010 -0.00172 0.0006 p=0.00355 p=0.003752
APOE4
   -/- - - - - - -
   +/- 0.121 0.042 p=0.00446 X2(2)=60.6 0.00588 0.0006 p<0.00001 X2(2)=120.6
   +/+ 0.226 0.065 p=0.00048 p<0.00001 0.00777 0.0009 p<0.00001 p<0.00001
Education
   Primary 0.352 0.057 p<0.00001 X2(3)=47.4 -0.00250 0.0008 p=0.00224 X2(3)=26.6
   Secondary 0.362 0.056 p<0.00001 p<0.00001 -0.00226 0.0008 p=0.00532 p<0.00001
   Tertiary 0.200 0.050 p=0.00005 -0.00375 0.0007 p<0.00001

















Main Effect Interaction Effect (with time)
All Supplements 0.03760 0.04024 p=0.35018 0.00023
Zinc 0.07117 0.09972 p=0.04755 0.00207
0.0006 p=0.68480
Selenium 0.10269 0.12239 p=0.40145 0.00218 0.0014 p=0.11098
Multi-vitamin 0.00351 0.04150 p=0.93250 0.00024
0.0008 p=0.02023
Magnesium 0.11233 0.06666 p=0.09198 0.00059 0.0009 p=0.49260
Iron 0.12126 0.07580 p=0.11007 0.00192
Calcium 0.09880 0.04305 p=0.02172 0.00117 0.0006 p=0.05361
C
Figure 1. Zinc supplementation use was associated with reduced prevalence of Alzheimer’s disease and slowed cognitive decline during disease development. A, Table of baseline statistics
by supplement showing nominal differences in nuisance variables, such as age, gender, APOE4 status, and significant differences in the prevalence of cognitive dysfunction. Shown are the num-
ber of participants for each variable with percentage of total in parentheses; or for numerical variables, the means and SD are shown. *p, 0.05; **p, 0.01; ***p, 0.001; compared with
no supplement use. “Statistics” column reports the omnibus tests. B, A stacked bar chart showing the proportions of cognitive diagnosis. Zinc supplement use was associated with the lowest
proportion of Alzheimer’s disease. This was significantly different from “no supplement” use group as reported in A. Dashed lines indicate proportions of cognitive diagnoses in the “no supple-
ment” group. C, Summary table of the final negative binomial GLMM with MMSE failures as the dependent variable. Zinc supplement use was associated with significantly slowed cognitive
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microglia morphology. There was no change in plasma zinc
between all groups (diet main effect: F(2,68) = 0.86, p= 0.43), but a
decrease in zinc content in the bone was seen in WT and APP/
PS1 mice fed a ZD diet, indicating a change in long-term zinc
status (Fig. 2B,C) (diet main effect: F(2,64) = 4.26, p=0.018).
Severe zinc deficiency can lead to weight loss, but the marginal
ZD diet used here had no effect on body weight compared with
normal diet (Fig. 2D) (diet main effect: F(2,43) = 0.49, p=0.616)
or fat mass (data not shown, diet main effect: F(2,74) = 0.14,
p=0.866) of the WT or APP/PS1 mice. These data suggest that
we had modeled a subclinical level of zinc deficiency (Beattie et
al., 2012).
The mild zinc deficiency causes reversible cognitive decline in
the APP/PS1 mice while having no effect on the cognitive per-
formance of the WT mice (Y-maze task three-way interaction:
x 2(6) = 19.33, p=0.004). In WT mice, there was no effect of ZD
diet on memory over 6months as analyzed by the Y-maze (Z =
0.16, p=1.000) and novel smell tests (Z = 0.16, p=0.743)
(Fig. 2E,G). As expected, the APP/PS1 mice showed no signifi-
cant reduction in cognitive performance over the course of the
experiment on the ZN diet in the Y-maze (Z = 1.81, p=0.281)
or novel smell tests (Z = 0.05, p=1.000) (Fig. 2F,H). However,
APP/PS1mice on a ZD diet showed accelerated memory loss at 3
months in the Y-maze test (Z = 2.81, p=0.024), and this was
worse after 6 months on the ZD diet (Z = 3.75, p= 0.001) (Fig.
2F). This cognitive impairment measured by Y-maze of APP/PS1
mice fed a ZD diet for 3 months was reversed by returning the
mice to a ZN diet for 3 months (Z = 3.93, p, 0.001) (Fig. 2F).
Similar, but less dramatic, trends were observed in the novel
smell test in response to a ZD diet in the APP/PS1mice (Fig. 2H)
(three-way interaction: x 2(6) = 14.53, p= 0.024). These data sug-
gest that zinc deficiency is causally accelerating cognitive decline
in Alzheimer’s disease and that these cognitive deficits are revers-
ible. They also place our epidemiological observations in people
in context, suggesting that the association of improved cognitive
outcome in patients taking zinc supplements is because of a
direct causal relationship between zinc status and Alzheimer’s
disease progression.
Zinc deficiency does not alter plaque burden, microglia
activation, or age-related cognitive decline
The effects of zinc deficiency on memory were not because of
altered Ab plaque burden as plaque burden was not significantly
different between APP/PS1 mice fed a ZN or a ZD diet (Fig.
3A,B) (two-way interaction: F(3,61) = 1.93, p=0.154). Similarly,
levels of microglia with activated morphology, typically associ-
ated with plaques, were not altered between treatment groups
(Fig. 3C) (two-way interaction: F(3,49) = 0.06, p=0.940). We then
hypothesized that the effects of zinc deficiency may be common
with NLRP3-dependent age-related cognitive decline (Youm et
al., 2013). Thus, we placed 20-month-old C57BL/6J mice on a
ZD diet for 3 months, with 3-month-old mice as young controls.
No acceleration in cognitive decline after a ZD diet was observed
at either age in the Y-maze task (three-way interaction: x 2(7) =
7.34, p= 0.394) or Morris water maze task (interaction term:
F(1) = 0.284, p=0.570), indicating that the effect of zinc defi-
ciency seen in the APP/PS1 mice was specific to amyloidopathy
and its downstream effects (Fig. 3D,E). To elucidate the mecha-
nism of zinc deficiency-induced cognitive decline in APP/PS1
mice, RNAseq was performed on the whole hippocampal
homogenate. However, no substantial differences in transcrip-
tome were observed between genotype or diet (Fig. 3F,G). We
hypothesized therefore that transcriptional differences could be
occurring primarily in the periplaque regions, which were
masked in the hippocampal RNAseq data (Fig. 3F,G) by homog-
enizing the whole tissue. To investigate this potential locality of
transcriptional changes, we utilized laser capture microdissection
to probe gene expression in the periplaque regions of 8- to
9-month-old APP/PS1 mice (Fig. 3H). Performing qPCR on the
established the Alzheimer’s disease-linked gene trem2 and the
inflammatory genes for nlrp3 and il-1b , we confirmed that tran-
scriptional changes were largely confined to the periplaque
regions (Fig. 3I) (periplaque main effect: trem2 x 2(1) = 28.40,
p, 0.001; il-1b x 2(1) = 32.21, p, 0.001; nlrp3 x
2
(1) = 13.93,
p, 0.001). Given that NLRP3 activation has been strongly linked
to memory impairment in Alzheimer’s disease (Heneka et al.,
2013; Daniels et al., 2016) and that NLRP3 is activated by zinc
deficiency (Summersgill et al., 2014), we hypothesized that accel-
erated memory impairment in the APP/PS1 mice on the ZD diet
is because of a periplaque nlrp3 response (Heneka et al., 2013;
Daniels et al., 2016; Dempsey et al., 2017; Venegas et al., 2017;
White et al., 2017).
Zinc deficiency activates the NLRP3 inflammasome and
potentiates NLRP3 responses to stimuli, while zinc
supplementation inhibits NLRP3 activation
To investigate the potential regulation of NLRP3 by zinc status,
in vitro methods were used. We previously established that pri-
mary BMDMs have similar NLRP3 responses as microglia,
mixed glial cultures, and ex vivo brain tissue slices, therefore rep-
resent a robust and high throughput method for investigating
NLRP3 activation (Daniels et al., 2016; Hoyle et al., 2020).
BMDMs were primed with LPS and then treated with the
zinc chelator TPEN (1-30 mM, 4 h) to cause zinc depletion.
Analysis of the supernatant showed TPEN-induced zinc deple-
tion induced-1b release in a concentration-dependent manner
(F(4,20) = 25.28, p, 0.001) (Fig. 4A). Zinc depletion (TPEN 10
mM, 4 h) in LPS-primed BMDMs also caused oligomerization of
ASC, caspase-1 activation, and gasdermin-D cleavage, and this
was NLRP3-dependent as it was inhibited by the selective
NLRP3 inhibitor MCC950 (Fig. 4Bi). Conversely, zinc sup-
plementation (with ZnCl2) in LPS-primed BMDMs blocked
established NLRP3 activators, including silica, by inhibiting
IL-1b release (F(5,12) = 122.0, p, 0.001), ASC oligomeriza-
tion, caspase-1 and gasdermin D cleavage (Fig. 4Bii,C). We
then investigated potential interactions between Ab and
zinc depletion. Using BMDMs, we found that only Ab 42
oligomer treatment followed by TPEN was sufficient to
induce IL-1b secretion, which was inhibited by MCC950
(Fig. 4D). The effects of TPEN were then confirmed in LPS-
primed mixed glial cultures, and again TPEN treatment
induced IL-1b release, which was inhibited by MCC950
(F(5,12) = 20.18, p, 0.001) (Fig. 4E). Using LPS-primed
mixed glia, we also found that TPEN was also able to exacer-
bate Ab 42 oligomer-induced IL-1b secretion (F(3,8) = 8.06,
p = 0.008) (Fig. 4F). To investigate whether TPEN-induced
/
decline. Shown are the maximum likelihood estimates (“Estimate” columns) with Laplace
estimates of the SE (“Standard Error” columns), Z value and p value from the Wald approxi-
mation (“p-value” columns), as well as, the significance of inclusion of the variable in the
model evaluated using the log-likelihood ratio test, x 2 (“Statistics of inclusion” columns). D,
E, The effect of supplement use on predicted cognitive decline of an LMCI, 70-year-old
female as measured by MMSE scores. Plots model the effect of zinc only supplement use (E)
and any supplement (combined) use (D) with no supplement use modeled as the control
group in both plots. CN, Cognitively normal; EMCI, early MCI; LMCI, late MCI; AD, Alzheimer’s
disease; ADAS, Alzheimer’s Disease Assessment Scale. ns, not significant
Rivers-Auty et al. · Zinc Status, Inflammation, and Alzheimer’s Disease J. Neurosci., March 31, 2021 • 41(13):3025–3038 • 3031
zinc depletion caused inflammasome specks in microglia,
ASC-citrine-expressing microglia were isolated from adult
mice (Tzeng et al., 2016). Zinc depletion resulted in speck
formation, which was observed with live cell imaging and
the NLRP3 inhibitors MCC950 (Coll et al., 2015) and
NBC19 (Baldwin et al., 2017) were found to inhibit ASC
speck formation (Fig. 4G,H) (MCC950, Z = 6.34,
p, 0.001; NBC19, Z = 26.80, p, 0.001). Collectively,
these experiments indicate that zinc status can influence
NLRP3 activity. Zinc deficiency acts as an NLRP3 activating
and potentiating stimuli in macrophages, microglia, and
mixed glia, while zinc supplementation is inhibitory of
NLRP3 activation. Critically, we found that the combina-
tion of zinc deficiency and amyloidopathy is sufficient to
induce NLRP3 activation and IL-1b release in mixed glia
(and macrophages).
Zinc deficiency accelerates cognitive decline in the APP/PS1
mouse model of Alzheimer’s disease through an NLRP3-
dependent mechanism
As we had established that zinc deficiency could potentiate
NLRP3 responses in vitro, we hypothesized that zinc deficiency
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Figure 2. Subclinical zinc deficiency accelerates memory deficits in an animal model of Alzheimer’s disease without effecting plasma zinc or weight gain. A, Timeline of the zinc deficiency
experiment in APPswe/PSd E9 (APP/PS1) and WT mice. B, C, Inductively coupled plasma mass spectrometry revealed that 6 months on a ZD diet (3 mg/kg) induced sustained subclinical zinc
deficiency as measured by reduced bone zinc levels (B) but not plasma zinc levels (C). D, ZD diet did not affect growth of the animals with no effect on body weight change during the course
of the study. E, F, The Y-maze memory task revealed that a ZD diet induced a significant memory deficit in the APP/PS1 mice compared with mice on a ZN diet (35 mg/kg). These deficits were
reversed by returning these mice onto a ZN for 3 months (ZD/ZN group; F). G, H, The novel smell recognition task revealed significant deficits in the APP/PS1 ZD group compared with the ZN
group (H). Animals returned to the ZN diet at 6 months old did not return to cognitive normal performance. In WT mice, no deficits were observed in the Y-maze or the novel smell recognition
tasks on any diet combination (E,G). *p, 0.05; ***p, 0.001; compared with the ZN group within the same genotype. Holm-Sidak-corrected post hoc analysis. Data are mean 6 SEM. WT
ZN, n= 13; WT ZD, n= 15; WT ZD/ZN, n= 12; APP/PS1 ZN, n= 13; APP/PS1 ZD, n= 11; APP/PS1 ZD/ZN, n= 11.
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Figure 3. The effects of zinc deficiency alter the local response to the plaque without altering plaque burden or age-related cognitive decline. A, Six months on a ZD (3 mg/kg) diet did not
alter Ab plaque burden in APPswe/PSd E9 (APP/PS1) mice compared with ZN (35 mg/kg) controls. The zinc recovery group was also unchanged (ZD diet for 3 months followed by a ZN diet
for 3 months; ZD/ZN). B, Example images of Ab plaque burden. C, No differences were observed in microglia morphology between any diet combination, measured as percentage of microglia
in an amoeboid phenotype. A-C, Sections were incubated with 6e10 (Ab ) or Iba1 (microglia) antibodies, visualized with DAB nickel (3,39-diaminobenzidine, nickel sulfate) staining averaged
across 6 coronal hippocampal sections per mouse. Scale bars, 500mm. ***p, 0.001, main effect of genotype (two-way ANOVA). D, E, Unlike in the APP/PS1 mouse, zinc deficiency did not
accelerate age-related cognitive decline, as measured by the Y-maze, in 20-month-old C57B/6J mice placed on a ZD diet for 3 months. Similarly, no changes were observed in the 3-month-old
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NLRP3 inflammasome. To test this hypothesis, we crossed WT
and APP/PS1 mice with nlrp3/ mice to generate four experi-
mental groups of mice: WT, nlrp3/, APP/PS1, and APP/PS1/
nlrp3/. Three-month-old animals were fed either a ZN or ZD
diet for 6 months before memory assessment using the Y-maze.
As above, there was no effect of a ZD diet on the memory of WT
mice (t(72) = 0.33, p= 1.000) or in nlrp3/ mice (t(72) = 0.81,
p=1.000) (Fig. 5A). Also, as previously noted, the ZD diet caused
memory impairment in APP/PS1 mice (t(72) = 8.06, p, 0.001)
(Fig. 5A). However, the zinc deficiency-induced memory impair-
ment in APP/PS1mice was abolished in APP/PS1/nlrp3/ mice
(t(72) = 4.54, p, 0.001) (Fig. 5A). These data suggest that the
effects of zinc deficiency on memory depend on NLRP3. These
protective effects of NLRP3 deficiency on memory after zinc
deficiency were independent of plaque burden or microglia acti-
vation as there was no significant difference in these parameters
in APP/PS1 mice with or without nlrp3 (three-way interaction
term: plaque F(1,46) = 1.15, p=0.290; microglia F(1,46) = 0.49,
p=0.488) (Fig. 5B–D).
Discussion
Using patient data, animal models, and cell culture methods,
we have provided evidence that zinc status is important in
Alzheimer’s disease progression, and specifically that zinc defi-
ciency accelerated cognitive decline in an Alzheimer’s disease
model through potentiating inflammatory responses mediated
by the NLRP3 inflammasome.
Our epidemiological evidence is supported by numerous pre-
vious studies which report that people with Alzheimer’s disease
have lower zinc serum levels (Ventriglia et al., 2015). Ventriglia
et al. (2015) performed a meta-analysis resulting in a pooled
sample of 1064 people with Alzheimer’s disease and 1894 healthy
controls and found that the serum or plasma zinc levels were
lower in people with Alzheimer’s disease with a standard mean
difference of 0.39, providing initial evidence of a cause associa-
tion of zinc deficiency and Alzheimer’s disease. The present
study takes this result further, demonstrating reduced cognitive
decline over time in people with MCI and Alzheimer’s disease in
individuals who are taking zinc supplements. While we acknowl-
edge that this association could be explained by an unaccounted
hidden variable, including lifestyle factors or unknown disease-
modifying medicines, most other mineral supplements were not
associated with an improvement in cognitive decline. To probe
this association and establish whether zinc status had a causal
effect on cognitive decline, we conducted in vivo experiments
using animal models of amyloidopathy.
There is clinical and preclinical evidence that excessive zinc
supplementation can lead to health complications by being
directly toxic, inhibiting copper absorption and through an inter-
action with amyloidopathy mechanisms (Fosmire, 1990; Yang et
al., 2013; Flinn et al., 2014; Craven et al., 2018). There is also ro-
bust evidence for high zinc deficiency prevalence among the el-
derly and in particular people with Alzheimer’s disease; hence,
we hypothesize that the association of zinc supplementation with
improved cognitive outcomes reported here was likely because of
the mitigation of zinc deficiency, rather than zinc supplementa-
tion exceeding recommended daily intake values (Briefel et al.,
2000; Ventriglia et al., 2015). Therefore, we designed the in vivo
experiments to investigate the effects of mild subclinical zinc
deficiency on cognitive decline in the APP/PS1 mouse model of
Alzheimer’s disease and addressed whether any effects could be
reversed by normalizing the levels of zinc. From this, we found
that ZD APP/PS1 mice had accelerated cognitive decline, but
these deficits could largely be reversed by returning the mice to a
diet that contained the recommended daily intake of zinc.
The literature describing the effects of zinc on amyloid depo-
sition is complex (Esler et al., 1996; Brown et al., 1997; Garai et
al., 2007; Rezaei-Ghaleh et al., 2011; Abelein et al., 2015; Lee et
al., 2018). We report no changes in plaque deposition induced
through zinc deficiency; therefore, we hypothesized that zinc was
modulating the response to the Alzheimer’s amyloidopathy
modeled by the APP/PS1 mice and not the amyloidopathy itself.
Using the same animal model, Stoltenberg et al. (2007) reported
a mild increase in plaque size in ZD animals. However, the zinc
deficiency induced by Stoltenberg et al. (2007) was more severe,
resulting in a 20% reduction in serum zinc levels. The present
study induced a mild subclinical zinc deficiency, which caused
no change to serum zinc levels and was only detected through
reduced zinc levels in the bone. Brain levels of zinc were not
measured here because of the complication of amyloid plaques
sequestering zinc. Indeed, Stoltenberg et al. (2007) could not
detect changes in cortical zinc even with the more severe zinc
deficiency likely because of this sequestration effect.
We saw an increase in nlrp3 expression in the periplaque
region in the hippocampus of the APP/PS1 mice. This observa-
tion and previous research support an importance of NLRP3 in
the response to amyloidopathy (Heneka et al., 2013; Daniels et
al., 2016). Using cellular models, we demonstrated that zinc defi-
ciency potentiated NLRP3 responses to stimuli, including
amyloid oligomers and that zinc inhibited NLRP3 responses
to activators, such as silica. The concentration of amyloid
used was supraphysiological to observe measurable inflam-
matory responses in the short time periods possible with the
culture methods utilized. This limitation was addressed by
translating these results in vivo. We established NLRP3 as
the critical mechanism by which zinc deficiency accelerated
cognitive decline in the APP/PS1 mouse model through
crossing nlrp3/ and APP/PS1 mouse lines. We demon-
strated that the cognitive decline induced by zinc deficiency
was completely abated in the APP/PS1 mice deficient in
NLRP3. Interestingly, we saw no changes in amyloid deposition in
the APP/PS1/nlrp3/ mice. Heneka et al. (2013) generated the
same mouse strain and did show reduced plaque burden; however,
in that study, 16-month-old mice were used. Therefore, it may be
the later stages of the pathology in which NLRP3 plays a role in
plaque deposition. Given the excellent research linking NLRP3 to
the aging process (Youm et al., 2013), the age difference between
/
“young” C57B/6J controls. This suggested that zinc deficiency was altering an amyloid-spe-
cific response, such as NLRP3-dependent inflammation. F, G, Zinc content in the diet had no
effect on the transcriptome in whole hippocampal tissue of APP/PS1 and WT mice. F, A prin-
cipal component analysis (PCA) of the transcriptome data showing no clustering of the WT
or APP/PS1 mice or the ZD and ZN diet. G, Volcano plot of genes comparing APP/PS1 mice
on a ZN or ZD diet showing minimal effects of diet with only one gene found to be signifi-
cantly different following false discovery rate (FDR) adjustment (n= 6/group). H, I, To estab-
lish whether there was a local response in APP/PS1 mice, periplaque regions (100mm
diameter) and plaque-free tissue from 8- to 9-month-old APP/PS1 mice were isolated using
laser capture (H) and probed for the plaque-associated gene trem2 (Ii) and the inflammatory
genes nlrp3 (Iii) and il-1b (Iiii); and from this, it was found that the nlrp3/il-1b response
is very tightly associated to the periplaque region (n= 3, for all groups). **p, 0.01;
***p, 0.001; versus plaque containing region. Plaques were identified with Congo red
staining. Holm-Sidak-corrected post hoc analysis. Data are mean 6 SEM. A-C, WT ZN,
n= 13; WT ZD, n= 15; WT ZD/ZN, n= 12; APP/PS1 ZN, n= 13; APP/PS1 ZD, n= 11; APP/
PS1 ZD/ZN, n= 11. D, E, Young ZN, n =15; Young ZD, n= 15; Aged ZN, n= 11; Aged ZD,
n= 12 (,15 because of attrition).
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Figure 4. Zinc deficiency activates the NLRP3 inflammasome and potentiates NLRP3 responses to stimuli, while zinc supplementation inhibits NLRP3 activation. A-D, Primary BMDM experi-
ments demonstrating that zinc deficiency activates the NLRP3 inflammasome and zinc supplementation inhibits NLRP3 inflammasome activation. A, Enhanced IL-1b release from ZD macro-
phages (BMDM), which were primed with LPS (1mg/ml, 4 h) and then treated with increasing concentrations of the zinc chelation agent TPEN for 4 h. B, BMDMs were primed (LPS 1mg/ml,
4 h) and treated with TPEN (10 mM) with and without NLRP3 inhibition by MCC950 (10 mM) (Bi) or silica (300mg/ml) with and without ZnCl2 (200 mM) supplementation (Bii); the cells were
lysed in the media and probed for ASC oligomerization, IL-1b cleavage (17 kDa), (casp 1) activation (p10), and gasdermin D cleavage. C, Zinc supplementation inhibits IL-1b release; BMDMs
were primed (LPS 1mg/ml, 4 h) and treated with silica (300mg/ml) in the presence of increasing concentrations of ZnCl2. D, BMDMs treated with TPEN (10 mM) and amyloid oligomers
(10mg/ml, NB no LPS priming) for 24 h release IL-1b , which is inhibited by MCC950 treatment (10 mM). *p, 0.05; **p, 0.01; ***p, 0.001; versus no treatment or LPS control.
###p, 0.001 versus activated group (Amyloid1TPEN). E, F, Confirmation experiments in mixed glial cultures demonstrating that LPS-primed BMDMs and mixed glial cultures have similar
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Heneka et al. (2013) and the present study could explain this
difference.
Previous research has demonstrated that zinc chelation with
clioquinol impedes the matrix metallopeptidase 9 processing of
pro-BDNF, perturbing synapse formation and cognitive per-
formance (Frazzini et al., 2018). Furthermore, zinc supplementa-
tion in the 3xTg mouse model of Alzheimer’s disease was found
to prevent cognitive decline through increasing BDNF levels and
mitigating tau, amyloid, and mitochondrial Alzheimer’s disease-
associated pathology (Corona et al., 2010). The RNAseq per-
formed here found no effects of zinc deficiency on expression of
genes downstream of BDNF signaling (e.g., neuropeptide Y).
One explanation for this incongruence is the time frame and se-
verity of zinc deficiency. Zinc chelation likely induced a more
severe reduction in bioavailable zinc than what was observed in
the present study. Additionally, Corona et al. (2010)
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Figure 5. Zinc deficiency accelerates cognitive decline in the APP/PS1 mouse model of Alzheimer’s disease through an NLRP3-dependent mechanism. A, APP/PS1 and C57BL/6J (WT) litter-
mate mice were crossed with nlrp3/ mice. Three-month-old mice from each genotype combination were placed on a ZD (3mg/kg) or ZN (35 mg/kg) diet for 6 months and were then
assessed using the Y-maze memory task. Memory deficits were seen in the APP/PS1 mice on a ZD diet but not on a ZN diet. However, APP/PS1/NLRP3/ mice on a ZD diet did not have
memory deficits. B, D, No effect of diet or genotype was seen on Ab plaque burden in APP/PS1 mice, or on (C) microglia morphology measured as percentage of microglia in an amoeboid
phenotype in adjacent sections. B, C, Sections were incubated with 6e10 (Ab ) and Iba1 (microglia) antibodies, respectively, visualized with DAB nickel (3,39-diaminobenzidine, nickel sulfate)
staining averaged across 6 sagittal hippocampal sections per mouse. Scale bars, 250mm. ***p ,0.001 versus WT littermates of the same NLRP3 genotype and diet. ##p, 0.01 versus
nlrp3/ group of the same diet and APP/PS1 genotype conditions. Holm-Sidak-corrected post hoc analysis following three-way ANOVA (NLRP3 genotype, diet, APP/PS1 genotype). Data are
mean 6 SEM. WT/nlrp31/1 ZN, n= 12; WT/nlrp31/1 ZD, n= 14; WT/nlrp3/ ZN, n= 8; WT/nlrp3/ ZD, n= 9; APP/PS1/nlrp31/1 ZN, n= 8; APP/PS1/nlrp31/1 ZD, n= 11;
APP/PS1/nlrp3/ ZN, n= 13; APP/PS1/nlrp3/ ZD, n= 9.
/
NLRP3 responses to zinc deficiency. E, ZD primary mixed glia release IL-1b in an
NLRP3-dependent manner; primary murine mixed glia were primed with LPS (1 mg/
ml, 4 h) and then treated with TPEN (10 mM) or silica (300 mg/ml) for 4 h with and
without the NLRP3 inhibitor MCC950 (10 mM). F, LPS (1 mg/ml, 4 h) primed mixed
glia release more IL-1b in response to amyloid oligomers (10 mg/ml, 4 h) when
zinc deficiency is induced (TPEN, 10 mM). **p, 0.01 versus LPS alone control.
#p, 0.05 versus activated group (LPS/silica or LPS/TPEN). G, H, ZD (TPEN 10 mM)
primary ASC-citrine expressing microglia (primed with LPS; 1 mg/ml, 2 h) form
inflammasome specks over time (G,Hii, white arrows), which is inhibited by the
NLRP3 inhibitors MCC950 (10 mM) (Hiii) and NBC19 (2 mM) (Hiv). ***p, 0.001 ver-
sus vehicle control (LPS alone). ###p, 0.001 versus activated group (LPS/TPEN).
Holm-Sidak-corrected post hoc analysis following one-way (A,C,D), two-way (E,F),
or repeated-measures (G) ANOVA. Data are mean 6 SEM of 4 independent
experiments.
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administered zinc supplementation to mice for 11months, start-
ing at 1-month old mice. This was both a longer period than the
present study and began at an age where neurodevelopment is
ongoing. So, while in the present study we see no evidence of
BDNF modulation, it is likely this pathway is affected in other
modalities of zinc deficiency and supplementation.
Managing Alzheimer’s disease is currently one of the greatest
societal problems. An increasing prevalence linked to an aging
population, with limited treatment options, is creating a global
crisis. The NLRP3 inflammasome has been identified as a thera-
peutic target for the treatment of Alzheimer’s disease, and there
are many pharmaceutical and academic initiatives underway to
develop new small-molecule inhibitors of the NLRP3 inflamma-
some (e.g., MCC950 and NBCs) (Coll et al., 2015; Baldwin et al.,
2017). The possibility of drug repurposing has also been identi-
fied for targeting NLRP3 in Alzheimer’s disease (Daniels et al.,
2016). Here, we show that, coupled to these initiatives, the nutri-
tional status, particularly of zinc, could be assessed and used to
treat groups of people with Alzheimer’s disease shown to be at
risk of zinc deficiency. In theory, zinc supplementation or dietary
improvements could be a cheap, rapid, low-risk, and easy
enhancement to patient care.
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